Alvogen Korea Holdings Ltd. announced that it will issue 264,347 common shares at an issue price of KRW 111,670 per share for the gross proceeds of KRW 29,519,629,490 on September 25, 2023. The transaction will include participation from returning investor Lotus Pharmaceutical Co., Ltd. The transaction has been approved by the board of directors of the company.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
286.5 TWD | -1.72% | +2.69% | +5.33% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.33% | 2.39B | |
+37.78% | 705B | |
+32.82% | 583B | |
-3.51% | 364B | |
+19.94% | 332B | |
+5.14% | 291B | |
+16.64% | 238B | |
-4.13% | 210B | |
+10.63% | 209B | |
+9.32% | 169B |
- Stock Market
- Equities
- 1795 Stock
- News Lotus Pharmaceutical Co., Ltd.
- Alvogen Korea Holdings Ltd. announced that it expects to receive KRW 29.51962949 billion in funding from Lotus Pharmaceutical Co., Ltd.